Boehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience in COPD), to better understand the disease and how it can be treated ...

The heritage of Boehringer Ingelheim in developing medicines for ... innovative treatments for chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis, lung cancer ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

"We are excited to be collaborating with an industry leader like Boehringer Ingelheim to deliver a more seamless digital health experience that can enable their COPD patients to better manage ...

Boehringer Ingelheim and three of its rivals — AstraZeneca ... Tens of millions of Americans suffer from asthma and COPD and rely on inhalers to breathe — about 25 million Americans have ...

The global Chronic Obstructive Pulmonary Disease (COPD) treatment market is projected to experience steady growth over the ...

Dupilumab, an injectable interleukin (IL)-4 and IL-13 pathway inhibitor, recently received FDA approval as the first-ever ...

Medscape Medical News, March 14, 2024 Boehringer to Cap Out-of-pocket Inhaler Cost At $35 Per Month Boehringer Ingelheim will cap ... Priority Review for Add-On COPD Care The first new COPD ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...

The PREPOCOL study was sponsored by an educational contribution from Boehringer-Ingelheim and Pfizer, which did not participate in study design, sample collection, data analysis, or publication.